Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit

I A Rowe; D D Houlihan; D J Mutimer

doi:10.1111/apt.12018

Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit

I A Rowe, D D Houlihan, D J Mutimer

Immunology and Immunotherapy

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Protease inhibitors have improved sustained virological response (SVR) rates for subjects with genotype 1 hepatitis C virus infection (HCV). There is however uncertainty regarding how, and in whom, these agents should be used. In previously treated subjects, prior response to interferon has a major effect on SVR rates with protease inhibitor therapy.

Original language	English
Pages (from-to)	670-9
Number of pages	10
Journal	Alimentary Pharmacology & Therapeutics
Volume	36
Issue number	7
DOIs	https://doi.org/10.1111/apt.12018
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/apt.12018

Mesenchymal Stem Cell Homing to the Chronically Injured Liver
Newsome, P. & Frampton, J.
Medical Research Council
3/08/09 → 2/08/12
Project: Research Councils
A Role for Hepatic Sinusoidal Endothelial Cell Antigen Presentation in the Generation of Immune Tolerance in Hepatitis C
Rowe, I.
Medical Research Council
1/01/09 → 4/01/12
Project: Research Councils

Cite this

@article{19794556eae74183a7ce94449658fd3d,

title = "Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit",

abstract = "Protease inhibitors have improved sustained virological response (SVR) rates for subjects with genotype 1 hepatitis C virus infection (HCV). There is however uncertainty regarding how, and in whom, these agents should be used. In previously treated subjects, prior response to interferon has a major effect on SVR rates with protease inhibitor therapy.",

author = "Rowe, {I A} and Houlihan, {D D} and Mutimer, {D J}",

note = "{\textcopyright} 2012 Blackwell Publishing Ltd.",

year = "2012",

doi = "10.1111/apt.12018",

language = "English",

volume = "36",

pages = "670--9",

journal = "Alimentary Pharmacology & Therapeutics",

issn = "1365-2036",

publisher = "Wiley",

number = "7",

}

TY - JOUR

T1 - Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit

AU - Rowe, I A

AU - Houlihan, D D

AU - Mutimer, D J

PY - 2012

Y1 - 2012

N2 - Protease inhibitors have improved sustained virological response (SVR) rates for subjects with genotype 1 hepatitis C virus infection (HCV). There is however uncertainty regarding how, and in whom, these agents should be used. In previously treated subjects, prior response to interferon has a major effect on SVR rates with protease inhibitor therapy.

AB - Protease inhibitors have improved sustained virological response (SVR) rates for subjects with genotype 1 hepatitis C virus infection (HCV). There is however uncertainty regarding how, and in whom, these agents should be used. In previously treated subjects, prior response to interferon has a major effect on SVR rates with protease inhibitor therapy.

U2 - 10.1111/apt.12018

DO - 10.1111/apt.12018

M3 - Article

C2 - 22906241

SN - 1365-2036

VL - 36

SP - 670

EP - 679

JO - Alimentary Pharmacology & Therapeutics

JF - Alimentary Pharmacology & Therapeutics

IS - 7

ER -

Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit

Abstract

UN SDGs

Access to Document

Fingerprint

Projects

Mesenchymal Stem Cell Homing to the Chronically Injured Liver

A Role for Hepatic Sinusoidal Endothelial Cell Antigen Presentation in the Generation of Immune Tolerance in Hepatitis C

Cite this